SB 3228, the Stop the Importation and Manufacturing of Synthetic Analogues Act of 2025 (SIMSA Act of 2025), would amend the Controlled Substances Act to create a new sixth drug category, “Schedule A,” for imported or offered-for-import substances that are chemically similar to controlled substances and have substantially similar or greater stimulant, depressant, or hallucinogenic effects. The bill is aimed at synthetic analogues and other emerging drugs that are not already listed in existing schedules, and it gives the Attorney General authority to temporarily place qualifying substances into Schedule A and later make that scheduling permanent through rulemaking.
The bill also expands import, export, labeling, registration, and penalty provisions to cover Schedule A substances. It would make it unlawful to import or export such substances for manufacture, distribution, or dispensing unless they are clearly labeled using IUPAC nomenclature, with limited exemptions for FDA-approved products and certain investigational clinical-trial products. It further establishes registration requirements for importers and exporters using Schedule A substances for research, analytical, or industrial purposes, and it adds conforming changes throughout the Controlled Substances Import and Export Act so Schedule A is treated similarly to other controlled substances for trafficking and border-control purposes.
On enforcement, the bill creates specific criminal penalties for violations involving Schedule A substances, including imprisonment terms, fines, supervised release, and enhanced penalties for repeat offenders or cases involving death or serious bodily injury. It also includes a sentencing-review mechanism allowing people convicted of covered offenses to seek resentencing if a Schedule A substance is later descheduled or moved to a lower-penalty schedule. The bill preserves existing authority to prosecute controlled substance analogues and does not limit the Attorney General’s current scheduling powers under the Controlled Substances Act.
The general sentiment reflected in the bill’s sponsorship is strongly supportive of tighter federal control over synthetic analogues, with bipartisan introduction by Senators Grassley, Hassan, Ernst, Shaheen, and Capito suggesting cross-party interest in addressing drug trafficking and public-health harms. No committee debate, votes, or recorded opposition are provided in the materials, so there is no documented floor or committee sentiment beyond the bill’s text and sponsorship.
The main points of contention likely center on the breadth of the new Schedule A category, the Attorney General’s temporary scheduling authority, and the bill’s limits on judicial review of temporary orders. Potential concerns also include how the bill would affect legitimate research, manufacturing, and clinical-trial activity, although the text includes exemptions and registration pathways intended to protect those uses. Another possible issue is whether the new schedule and penalties are sufficiently precise to avoid overbroad application to substances with uncertain scientific profiles.
The bill would amend multiple provisions of the Controlled Substances Act and the Controlled Substances Import and Export Act to add a new Schedule A and extend federal trafficking, import/export, labeling, registration, and penalty rules to substances meeting the bill’s analogue-based definition. It would also create new procedures for temporary and permanent scheduling, impose new criminal penalties for Schedule A violations, and establish a resentencing process if a substance is later removed from or moved within the schedules. Affected parties would include importers, exporters, manufacturers, distributors, researchers, clinical-trial sponsors, and federal enforcement agencies, especially the Attorney General and the Department of Health and Human Services.
The available context suggests generally favorable sentiment toward the bill’s purpose of combating synthetic drug analogues and importation of dangerous new substances. The bill is bipartisan in sponsorship, and there are no recorded committee transcripts or votes showing opposition or amendment activity. Because no debate or vote history is provided, the record does not show any formalized support or resistance beyond the bill’s introduction and referral.
The most notable potential contention is the creation of Schedule A and the Attorney General’s authority to temporarily schedule substances without judicial review, which could raise due-process and administrative-law concerns. Another likely issue is the definition of a Schedule A substance, which relies on chemical similarity and predicted effects, potentially creating disputes over scientific evidence and scope. Researchers and regulated industry participants may also scrutinize the registration and labeling requirements, while criminal-justice advocates may focus on the severity of the new penalties and the breadth of conduct covered.